$LLY

$LLY COST WMT green…

$LLY pt raised $1,596 from $1,430 @ Morgan Stanley…

$LLY ceo on Cnbc…

$LLY - MOUNJARO REV: $10.7B (EST $9.95B) - FOUNDAYO REV: $184M (EST $231.2M) - SEES FY REV: $91.0B TO $92.0B (PREV $85.0B TO $87.0B) - SEES FY ADJ EPS…

$LLY Eli Lilly Q3 earnings — EPS $7.48 vs $6.61 est, beat, up 7% YoY — Revenue $24.397B vs $22.62B est, beat, up 39% YoY — EPS down 11% QoQ, revenue u…

$LLY - Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio…

$LLY - Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head tri…

$LLY - Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets…

$LLY - Lilly breaks ground in Richmond to expand American manufacturing of next-generation cancer medicines, advancing its build-out of 10 new U.S. si…

$LLY new record highs…

$LLY - Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress…

$LLY - Lilly confirms date and conference call for third-quarter 2026 financial results announcement…

$LLY - New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease cont…

$LLY highs…

$LLY ELI LILY: TALTZ AND ZEPBOUND TOGETHER SHOW BROADER BIOMARKER CHANGES VS. TALTZ ALONE || NEW PHASE 3B DATA ON LILLY'S TALTZ AND ZEPBOUND ADVANCE U…

$LLY - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic bio…

$LLY - Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its larges…

$LLY - Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults…

$LLY *LILLY'S RETATRUTIDE CUTS WEIGHT AVG 20.8% OVER 80 WKS IN PH. 3 *ELI LILLY - TO SUBMIT BIOLOGICS LICENSE APPLICATION FOR RETATRUTIDE IN Q1 2027…

$LLY - Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with ob…

$LLY tons of powerful news versus Novo on weight loss drugs. Being ignored - Cramer…

$LLY Eli Lilly: Foundayo Shows Greater Weight Loss and A1C Reduction vs. Oral Semaglutide 25 mg in Indirect Comparison ? • At 52 weeks, Foundayo 17.2…

$LLY - Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabe…

$LLY highs…

$LLY US FDA OKS LILLY'S ONSWIK…

$LLY BREAKS GROUND ON $6.5B HOUSTON PLANT TO MAKE ORAL GLP-1 DRUG FOUNDaYO Eli Lilly has started construction on a roughly 1M-square-foot manufacturin…

$LLY - Lilly breaks ground in Houston, one of ten U.S. manufacturing sites announced since 2020…

$LLY - Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health…

$LLY - Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference…

$LLY - FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes…